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Abstract: Osteoarthritis is one of the leading causes of disability in the elderly. The changes 
in the lubricating properties of synovial ﬂ  uid lead to signiﬁ  cant pain and loss of function. More 
than ten years have passed from the ﬁ  rst studies. Up till now many authors have supported 
intra-articular hyaluronan (HA) therapy as not only a symptom-modifying therapy but also a 
treatment which may signiﬁ  cantly decrease the rate of deterioration of joint structure. In this 
review we report data relative to knee and hip treatment. The ongoing studies continue to further 
our understanding of the fundamental mechanisms that likely underlie the therapeutic beneﬁ  ts 
of this treatment but, despite recent progress, many unresolved issues require further study. 
Large scale double blind controlled studies must be carried out to conﬁ  rm these promising data 
and produce meaningful guidelines.
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Introduction
Osteoarthritis is one of the leading causes of disability in the elderly. The changes in 
the lubricating properties of synovial ﬂ  uid lead to signiﬁ  cant pain and loss of function. 
Viscosupplementation, the injection of hyaluronic acid (HA) into the joints, improves 
the biochemical properties of synovial ﬂ  uid into osteoarthritis joints. The clinical effect 
is pain relief and disease modifying activity (Balazs and Denlinger 1993; Pelletier 
and Martel-Pelletier 1993).
Although there are many nonsurgical therapies available for the treatment of pain 
associated with osteoarthritis (OA), their long-term use and safety have not been 
systematically followed. Intra-articular (IA) hyaluronan therapy has been used in the 
treatment of symptoms associated with OA of the knee with a very favorable safety 
proﬁ  le (Pagnano and Westrich 2005). In this connection, the physiological and phar-
macological characteristics of HA have recently been reviewed. The high concentration 
of HA in spinal ﬂ  uid (SF) is essential for normal joint function. The altered proper-
ties of the synovial ﬂ  uid in OA, the decrease in molecular size and concentration of 
HA leads to reduced rheologic properties, which affect the lubrication and protection 
mechanism of action of IA hyaluronan and is probably more complex than previously 
thought (Maneiro et al 2004).
The hypothesis that HA could bind to speciﬁ  c receptors is now widely accepted. 
The cluster determinant 44 (CD44), the intracellular adhesion molecule-1 (ICAM-1) 
and the receptor for hyaluronate-mediated motility (RHAMM) expressed in many 
cells, are some of those implicated in the process (Hodge-Dufour et al 1997; Siegelman 
et al 1999). The binding of HA with its speciﬁ  c receptors has been reported to trigger 
various intracellular signal events such as cytokine release and stimulation of cell 
cycle proteins. The consequences of these interactions is to stimulate cell functional 
activities such as cell migration and proliferation (Cao et al 2004).Clinical Interventions in Aging 2008:3(2) 366
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More than ten years have passed since the original expla-
nation by Balazs and Denlinger (1993) that the favorable 
effects of IA HA therapy in OA was related only to the resto-
ration of SF rheological properties (Goldberg and Buckwalter 
2005). Many subsequent studies have supported that IA HA 
therapy is a symptom-modifying approach that has been 
found to be safe and effective for reducing pain due to OA of 
the knee and furthermore may also signiﬁ  cantly decrease the 
rate of deterioration of joint structure. This statement stems 
from different evidences. First of all, the complex biochemi-
cal effects of HAs in the synovium and extracellular matrix 
of the articular cartilage, including interactions between 
exogenously administered HA and articular cartilage, sub-
chondral bone, matrix proteoglycans, and collagens. In the 
second place, the effects of HA administration in animal 
models of OA, including total or partial meniscectomy and 
anterior cruciate ligament transectomy. Thirdly, the results of 
clinical trials using one HA, Hyalgan (sodium hyaluronate, 
molecular weight 500–730 kDa) that evaluated structural 
outcomes, such as joint-space width, chondrocyte density 
and vitality, and arthroscopic evaluation of chondropathy. 
Localized severe acute inﬂ  ammatory reactions reported with 
repeated treatment in some patients are not a class effect but 
may be linked to physicochemical characteristics of hylan-
based treatment (Arrich et al 2005; Pagnano and Westrich 
2005; Goldberg and Buckwalter 2005).
Studies on the effects of HAs of different molecular 
weight (MW) on speciﬁ  c receptors have shown that the 
results can vary depending on the size of the HA molecules 
used. For example low MH HA fragments generated during 
joint inﬂ  ammation may promote chemokine gene expression 
by macrophages. Ohkawara and colleagues (2000) noticed 
that HA preparation of MW 0.2 × 106 Da was more effec-
tive in maintaining the survaival of blood eosinophils than 
HA with an MW of 3 × 106 −6 × 106 Da, proposing that the 
effect derived from the increased expression of granulocyte 
macrophage colony-stimulating factor after CD44 activation 
(Ohkawara et al 2000).
Different HA products
Presently, there are several different HA products available 
for injection. However, the source of hyaluronic acid var-
ies. Some products are extracted from rooster combs but a 
contraindication to treatment would be an allergy to eggs 
or chicken.
Hyaluronic acid is available in a variety of products with 
different molecular weight ranging from 500 KD to more than 
90 millions D (Table 1). Hylans are cross-linked hyaluronic 
acids, which gives them a higher molecular weight and 
increased elastoviscous properties.
HA products in the intra-articular 
treatment of knee OA
The ﬁ  rst studies on the use of HA in human knee OA were 
carried out in the 1970s by Rydell and Balasz (1971) and 
Peyron and Balasz (1974). In 1974, Peyron injected 1, 2, 
or 3 ml of HA (Healon) in 23 knees and obtained positive 
responses in pain and function in 74% of patients. The treat-
ment with two injections of 2 ml HA each appeared to have 
the best outcome.
Recent papers have reviewed clinical trials published in 
the last years using different HA preparation and the results 
of these trials are summarized in Table 2.
Data support the beneﬁ  t and safety of repeated treatment 
with IA HA. Many trials indicate that sodium hyaluronate 
(molecular weight [MW] 500–730 kDa) is well tolerated and 
as effective after multiple courses of treatment as it is after 
a single course (Pagnano and Westrich 2005). Other data 
state that viscosupplementation is an effective treatment for 
patients with knee OA who have ongoing pain or are unable 
to tolerate conservative treatment or joint replacement.
Viscosupplementation appears to have a slower onset of 
action than intra-articular steroids, but the effect seems to 
last longer (Wang et al 2004).
HA not only relieves the symptoms of OA but also 
modiﬁ  es the structure of the diseased joint and the rate of 
Table 1 Molecular weights of hyaluronic acid (HA) products
Trade name  Molecular weight  Source  Mg/ml
Hyalgan  500–730 KDa  HA extracted from rooster combs  20 mg/2 ml
Hyalubrix   1500 KDa  Fermentative HA  30 mg/2 ml
Artz (Supartz)  800–1170 KDa  HA extracted from rooster combs  25 mg/2.5 ml
Synovial (Jointex)  800–1200 KDa HA  Fermentative HA  16 mg/ml
Synvisc  6000 KDa  HA extracted from rooster combs  16 mg/2 ml
Durolane  90 millions Da  Synthetic HA  20 mg/ 3 ml
Euﬂ  exxa  2.400–3.600 kDa  Fermentative HA  20 mg/2 mlClinical Interventions in Aging 2008:3(2) 367
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OA disease progression, at least early in the evolution of the 
disease process (Ohkawara et al 2000).
Based on the aforementioned analyses, viscosupple-
mentation is an effective treatment for OA of the knee with 
beneﬁ  cial effects on pain, function and patient global assess-
ment at different post injection periods but especially at the 
5 to 13 week post injection period with a dramatic effect on 
the reduction of NSAIDs monthly consumption.
However, there are few randomized head-to-head com-
parisons of different viscosupplements and readers should 
be cautious, therefore, in drawing conclusions regarding the 
relative value of different products.
In some analyses, viscosupplements were comparable in 
efﬁ  cacy to systemic forms of treatment, with more local reac-
tions but fewer systemic adverse events. In other analyses HA 
products had more prolonged effects than IA corticosteroids. 
Overall, the aforementioned analyses support the use of the 
HA class of products in the treatment of knee OA (Lo et al 
2003). In one systematic review, IA HA has not been proven 
clinically effective and may be associated with minimal and 
transient risk of adverse events (Arrich et al 2005).
At present no case of septic arthritis has been reported 
in any clinical trial. Most adverse events are minor and 
transient at the injection site. Painful post-injection reac-
tion occurred in 1%–2% of patients, the pain did not last 
more than 72 hours. Systemic allergic reactions due to 
individual hypersensitivity were rarely recorded. Therefore 
viscosupplementation seems to be an efﬁ  cacious and safe 
treatment.
The heterogeneity of these studies limits definitive 
conclusions on different treatment regimen with diverse 
molecular weight HA but in our opinion we think that the 
different HA products act with the same class effect (Axe 
and Shields 2005).
Table 2 Recent clinical trials using HA
Author / Year N trials Intervention Conclusions
Lo et al 2004 22 selected trials Hyalgan, Synvisc, Artzal, Suplasyn, 
BioHy, Orthovisc
Measurable effect when compared with 
placebo. Highest-molecular-weight HAs 
may be more. Heterogeneity of these 
studies limits deﬁ  nitive conclusions.
Aggarwal et al 2004 Five case series 13 RCTs Synvisc low-molecular-weight HA High-molecular-weight HAs effective. 
Conﬂ  icting results with low-molecular-
weight. Slower onset of action than 
intra-articular steroids, but the effect last 
longer.
Wang et al 2004 Twenty blinded randomized 
controlled trials
Hyaluronic acid versus placebo Therapeutic efﬁ  cacy and safety
Axe et al 2005 Potential use in the treatment of 
inﬂ  ammatory arthropathies (eg, 
acute joint trauma and fractures)
Hyaluronans Trials limited in design and patient 
number. Moderate results. Controlled 
clinical trials are warranted.
Goldberg et al 2005 A review on a Medline search 
through June 2004
Hyalgan, Supartz, Synvisc In addition to relieving the symptoms, 
HAs also modify the structure of the 
diseased joint and the rate of OA disease 
progression.
Arrich et al 2005 Twenty-two trials Hyaluronic acid The data available did not allow an 
appropriate assessment of any end point. 
Adverse events occurred slightly more 
often.
Bellamy et al 2005 Thirty-seven trials included 
comparisons of hyaluronan/hylan 
and placebo, nine trials included 
comparisons of intra-articular 
corticosteroids, and ﬁ  ve trials 
included comparisons of (NSAIDs)
Adant, Arthrum H, Artz (Artzal, 
Supartz), BioHy (Arthrease), Duro-
lane, Fermathron, Go-on, Hyalgan, 
Hylan G-F 20 (Synvisc Hylan G-F 
20), NRD-101, Orthovisc, Ostenil, 
Replasyn, SLM-10, Suplasyn, Synject 
and Zeel compositum
The effects against ‘placebo’ controls 
generally supported the efﬁ  cacy. Delayed 
effects on pain and function. Comparable 
efﬁ  cacy against NSAIDs and longer-term 
beneﬁ  ts against IA corticosteroids. Few 
adverse events were reported.
Pagnano et al 2005 Databases were searched using 
the terms hyaluronan, sodium 
hyaluronate, hyaluronic acid, hylan, 
hylan G-F 20
Hyaluronan, sodium hyaluronate, 
hyaluronic acid, hylan, hylan G-F 20
Hyaluronans are safe and effective in the 
treatment of pain. Sodium hyaluronate 
decrease the rate of deterioration of joint 
structure
Abbreviations: IA, intra articular; RCT, randomized controlled trials; HA, hyaluronic acid; OA, osteoarthritis.Clinical Interventions in Aging 2008:3(2) 368
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Furthermore preliminary data indicate a potential use for 
hyaluronans in the treatment of inﬂ  ammatory arthropathies 
(eg, acute joint trauma and fractures) that require long periods 
of immobilization, and in tissue engineering for chondral 
defects. Although the trials that have investigated the use 
of hyaluronan therapy for the management of traumatic 
and degenerative musculoskeletal disorders seen in sports 
medicine have limitations in design and patient number, the 
results have been promising and suggest that larger controlled 
clinical trials are warranted (Peyron and Balasz 1974).
HA products in the intra-articular 
treatment of hip OA
Few data exists in literature about the viscosupplementation 
of hip OA in spite of it is the second most common site of the 
disease after the knee (Pelletier and Martel-Pelletier 1993; 
Pagnano and Westrich 2005). One of the limiting factors 
for this practice might be related to the injection procedure. 
The intra-articular injection of the hip is not as easy as for 
the knee, mainly for anatomical features of the joint and the 
proximity of “sensitive” structures such as the femoral artery 
and nerves. Even though hip injection may be performed 
“blindly”, failure rate is nevertheless signiﬁ  cant (Jones et al 
1993) and when using a slow absorbing viscosupplement like 
hyaluronan, the potential local complications may jeopardize 
the therapeutic beneﬁ  t (Jackson et al 2002). For such reasons, 
it has been suggested to perform intra-articular injection of 
the hip under radiological or ultrasound control. Although 
several ultrasound guidance techniques were available 
(Qvistgaard et al 2001), we developed a personal one using 
an antero-superior approach (Migliore et al 2003).
Since no single or double blind randomized controlled trials 
have yet been published, we analyzed all the available trials on 
MEDLINE to assess viscosupplementation for the treatment 
of hip OA (Table 3).
The efﬁ  cacy data underlines signiﬁ  cant improvement in 
pain and function as has been shown in the knee OA stud-
ies despite the small size of the sample. The short period of 
observation has not seen a change in the natural history of the 
disease. In order to conﬁ  rm these promising data, large scale 
double blind controlled studies must be carried out.
Conclusions
The ongoing studies continue to further our understanding of 
the fundamental mechanisms that likely underlie the thera-
peutic beneﬁ  ts of this treatment. The meta-analysis in prog-
ress are further establishing a role for viscosupplementation 
in ameliorating the symptoms of knee and hip osteoarthritis. 
At the moment it is clear that viscosupplementation is more 
efﬁ  cacious in the initial and intermediate stages of OA more 
than at an advanced stages and that this therapy is exception-
ally safe compared with other OA treatments.
Despite recent progress, many unresolved issues 
require further study. These include determining the cost-
effectiveness of viscosupplementation, exploring the thera-
peutic effectiveness and safety, clearly deﬁ  ning the relation 
between molecular weight and the clinical effectiveness of 
the various hyaluronan products, establishing optimal dosing 
regiments, evaluating efﬁ  cacy in different OA populations, 
determining how to best incorporate viscosupplementation 
into the evolving OA treatments algorithms, exploring the 
potential for treatment of OA joints other than the knee, as 
already shown for the hip, and assessing potential synergistic 
or additive effects with other modalities such NSAIDs and 
SYSADOA.
It is encouraging that hyaluronan-based therapy is 
proving to be safe and effective for many patients with 
symptomatic hip and knee OA despite the fact that many 
unresolved issues requiring further study remain. If hyal-
uronan derivatives are eventually proven to have clear 
Table 3 Vscosupplementation studies for the treatment of hip osteoarthritis
Author year HA Nr of pts. Outcome measures Months of follow-up Nr.of injections
Brigantini 1994 Hyalgan 44 P/GA/NSAIDs 6 3–5
Brocq 2002 Synvisc 22 LI 1–6 1–2
Conrozier 2003 Synvisc 57 P/W/GA 3–6 1–2
Vad 2003 Synvisc 22 P/AAOS/LLCSS 12 3
Migliore 2003 Hyalgan 28 P/LI/NSAIDs NG 1–3
Caglar-Yagci 2005 Synvisc 14 P/LI/15 mWT 3 3
Berg 2004 Durolane 31 W/GA 3 1
Migliore 2005 Synvisc 26 P/LI/NSAIDs 12 1–2
Tikiz 2005 Synvisc vs Ostenil 25 vs 18 P/W/LI 6 3
Migliore 2006 Synvisc 36 P/W/NSAIDs 18 1–2
Abbreviations: P, pain; GA, global assessment; 15 mWT, 15-meter walking time; NSAIDs, NSAIDs consumption; LI, Lequesne index;   W, Womac index; AAOS, American 
Academy of Orthopaedic Surgeons; LLCSS, Lower Limb Core Scale Score.Clinical Interventions in Aging 2008:3(2) 369
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disease-modifying effects, it may then be reasonable to 
consider their use early in cartilage injury or disease, before 
the onset of syntomatic OA.
Additional well-designed randomized controlled trials with 
high methodological quality are needed to resolve the contin-
ued uncertainty about the therapeutic effects of different types 
of hyaluronic acid products on osteoarthritis in various clinical 
situations and patient populations (Wang et al 2004).
At the moment the Arthritis Foundation believes that while 
more studies are needed to determine the long-term results 
of such treatments, HA provides an option for people with 
knee OA who have not responded well to drug treatments or 
exercise and physical therapy. It also may be appropriate for 
those who may be at increased risk for upper gastrointestinal 
(GI) complications, such as patients who: are over 65 years 
old; are taking oral corticosteroids and/or anticoagulants; 
have a history of peptic ulcer disease or upper GI bleeding; 
are smokers; and consume high volumes of alcohol. HA also 
may be considered in patients with kidney failure.
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